The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501006 · Cited by 416
Self-citationMark, P. B., Stafford, L. K., Grams, M. E., Aalruz, H., Abd ElHafeez, S., Abdelgalil, A. A., Abdulkader, R. S., Abeywickrama, H. M., Abiodun, O. O., Abramov, D., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01853-7 · Cited by 418
“31 The most effective protective treatments for CKD are more recently established and have been implemented less uni formly than prevention programmes for communicable diseases (eg, improved sanitation and vaccinations), and non-communicable diseases (eg, cancer screening and cholesterol lowering),…”
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00271-7 · Cited by 359
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citationMapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“Although tolerability related to gastrointestinal side effects remains a concern, semaglutide has well-established efficacy in the management of T2DM and obesity, and has demonstrated renal and cardiovascular mortality benefits 301,302 .”
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Palaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“The FLOW trial studied the safety of semaglutide 1 mg once weekly in 3,533 people with T2D and chronic kidney disease, based on entry criteria of elevated urinary albumin excretion and reduced eGFR 117 .”
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Chen, V. L., Morgan, T. R., Rotman, Y., Patton, H. M., Cusi, K., Kanwal, F., & Kim, W. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001112 · Cited by 205
Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 204
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200
Self-citationRomagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease
Miguel, V., Shaw, I. W., & Kramann, R. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00889-z · Cited by 181
“…analysis, reported in 2024, demonstrated efficacy on the composite primary end point of time to first kidney failure (persistent eGFR decline 15 ml/min/1.73 m 2 or initiation of kidney replacement therapy), persistent ≥50% reduction in eGFR, or death from kidney or cardiovascular causes 170,171 .”
InfluentialThe impact of population ageing on the burden of chronic kidney disease
Chesnaye, N. C., Ortiz, A., Zoccali, C., Stel, V. S., & Jager, K. J. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00863-9 · Cited by 171
“The FLOW trial of semaglu-tide in participants with CKD (UACR >100 mg/g) and T2DM was stopped prematurely owing to efficacy for kidney, cardiovascular and all-cause mortality outcomes 160,163,164 .”
Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00509-4 · Cited by 176
“22 The effect of semaglutide should be considered in the context of the study population and previous studies of functional outcomes in patients with peripheral artery disease.”
Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168
Self-citationBorlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03374-z · Cited by 166
“…insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4) trial with tirzepatide 28 and the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial with semaglutide 29 , as well as other reno-protective drugs such as sodium–glucose cotransporter 2 inhibitors 30 .”
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 165
Self-citationECM formation and degradation during fibrosis, repair, and regeneration
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 176
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“…adverse cardiovascular events [22], decreased mortality in heart failure [23 – 27], and improvements in obstructive sleep apnea [21, 28], prediabetes [29, 30], chronic kidney disease [31], knee osteoarthritis [32], substance use disorders [33], and metabolic-associated steatotic liver disease [34].”
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“32 An observational study found that GLP-1 RAs users experienced reduced risks of mortality (6.8% vs. 12.9%, adjusted HR [aHR]: 0.57, 95% CI 0.51, 0.64), MACE (14.8% vs. 18.8%, aHR: 0.88, 95% CI 0.80, 0.96), and major adverse kidney events (10.8% vs. 16.0%, aHR: 0.73, 95% CI 0.66, 0.80) in patients…”
InfluentialMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“…adverse cardiovascular events [23], decreased mortality in heart failure [24 – 28], and improvements in obstructive sleep apnea [12,29], prediabetes [30,31], chronic kidney disease [32], knee osteoarthritis [33], substance use disorders [34], and metabolic-associated steatotic liver disease [35].”
Solomon, S. D., Ostrominski, J. W., Wang, X., Shah, S. J., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Verma, S., Abildstrøm, S. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.021 · Cited by 154
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.004 · Cited by 132
Self-citationCardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 183
“61 66 The FLOW trial was the first dedicated kidney outcome trial enrol-ling 3534 adults with diabetic CKD. 67 Compared with placebo, sema-glutide led to a 24% lower incidence of the primary renal composite endpoint of kidney failure, sustained 50% decline in eGFR, or CV or CKD death [HR: 0.76 (95%…”
InfluentialTheodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 174
Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
Claudel, S. E., & Verma, A. (2025) · Circulation · doi:10.1161/circulationaha.124.071079 · Cited by 160
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, C. X., Hribar, M., Baxter, S., Goetz, K., Swaminathan, S. S., Flowers, A., Brown, E. N., Toy, B., Xu, B., Chen, J., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.6555 · Cited by 129
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120
“In the FLOW trial, which is the only dedicated GLP-1 RA kidney outcome trial to date, semaglutide 1.0 mg once weekly reduced UACR by 32% 17 .”
InfluentialAdvances and challenges in kidney fibrosis therapeutics
Abbad, L., Estève, E., & Chatziantoniou, C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00934-5 · Cited by 146
“Activation of glucagon-like peptide 1 receptor (GLP1R) reduced albuminuria and prevented loss of kidney function 84–86 .”
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 163
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationAntiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“…bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic improvements and direct antiinflammatory actions on the intestine.”
Lupus nephritis-related chronic kidney disease
Lichtnekert, J., & Anders, H. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01158-w · Cited by 112
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 149
Navaneethan, S. D., Bansal, N., Cavanaugh, K. L., Chang, A. R., Crowley, S. T., Delgado, C., Estrella, M. M., Ghossein, C., Ikizler, T. A., Koncicki, H. M., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.003 · Cited by 126
“158,159 Notably, the rate of eGFR decline measured as slope was significantly slowed along with reduced risks of major atherosclerotic CVD events and all-cause mortality.”
Self-citationHerrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Lee, M. M. Y., Ghouri, N., Misra, A., Kang, Y. M., Rutter, M. K., Gerstein, H. C., McGuire, D. K., & Sattar, N. A. (2025) · Diabetes Care · doi:10.2337/dc24-1533 · Cited by 114
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 138
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 134
“Treatment with GLP1 receptor agonists and SGLT2 inhibitors should be prioritized in patients with T2DM and high cardiovascular risk, heart failure and CKD for organ protection 129 .”
InfluentialChiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationMechanisms of diabetic kidney disease and established and emerging treatments
Leon, V. M., Hilburg, R., & Suszták, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01171-3 · Cited by 123
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
“302,303 The SURPASS-4 trial 304 revealed that tirzepatide signi fi cantly reduced composite kidney endpoints by 40% and improved the annual eGFR decline by 2.2 mL/min per 1.73 m 2 per year.”
InfluentialRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
Self-citationJudge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 91
Self-citationLakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074545 · Cited by 70
Self-citationGLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“A previous meta-analysis 32 did not detect any significant association between GLP1-RA and cancer incidence, but recent long-term trials, 33,34 which were not available at the time, may have added new information on this topic.”
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
“…reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with T2D and chronic kidney disease [30], it is not known which mechanism(s) or processes from GLP-1/GLP-1R action delay the course of diabetic kidney disease, making these findings…”
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Recent trial evidence also suggests a beneficial effect of GLP-1 RA use on diabetic renal disease [167], which supports signals observed in the early GLP-1 trials [9].”
BackgroundSemaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Treatment of chronic kidney disease in older populations
Kishi, S., Kadoya, H., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00854-w · Cited by 73
“The randomized, controlled FLOW study directly compared the kidney and cardiovascular effects of weekly subcutaneous semaglutide with placebo in 3,533 patients adult patients with T2DM and CKD (mean age 66.6 ± 9.0 years; mean eGFR 47.0 ± 15.2) 105 .”
InfluentialAlicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae212 · Cited by 81
Self-citationMutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
“…on renal function decline (Table 1), HF hospitalization, major cardiovascular events (MACEs), and cardiovascular death [60,117,118], while GLP-1 RAs are recommended for those with BMI ≥ 35 kg/m 2 , A1c ≥ 9%, or taking high insulin doses, as they offer additional cardio-vascular benefits [106,128].”
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1455 · Cited by 61
Ortíz, A., Guerra, J. M. A., Chan, J. C. N., Jha, V., Kramer, H., Nicholas, S. B., Pavkov, M. E., Wanner, C., Wong, L. P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.005 · Cited by 91
Self-citationMahaffey, K. W., Tuttle, K. R., Arici, M., Baeres, F. M. M., Bakris, G. L., Charytan, D. M., Cherney, D. Z. I., Chernin, G., Correa‐Rotter, R., Gumprecht, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae613 · Cited by 78
Self-citationChen, J., Hsu, T., Liu, J.-H., Pan, H., Lai, C., Yang, S., & Wu, V. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.013 · Cited by 81
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“While there are newer and even more potent anti-obesity drugs on the horizon, semaglutide still garners attention for its non-diabetic and non-obesity benefits, specifically cardiovascular risk reduction, as well as improving renal outcomes [125,153].”
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100186 · Cited by 58
“New long-acting GLP-1 RA agents are highly effective for glycemic control, obesity treatment, and reducing cardiometabolic and kidney risk [21,50, 51].”
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citationIatridi, F., Carrero, J. J., Gall, É. C.-L., Kanbay, M., Luyckx, V. A., Shroff, R. C., & Ferro, C. J. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae209 · Cited by 87
“…for CKD [for example, the FLOW trial data on Semaglutide, a Glucagon Like Peptide-1 receptor agonist (GLP-1ra), on kidney disease progression [11 ] which was published after the KDIGO 2024 CKD Guideline], we chose to focus on the remaining Achilles’ heel of the global push to improve CKD…”
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 99
“Semaglutide also significantly reduced the kidney-specific component of the primary outcome and slowed the annual rate of eGFR decline [75].”
InfluentialGigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Kanbour, S., Ageeb, R. A., Malik, R. A., & Abu-Raddad, L. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00346-2 · Cited by 74
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 81
“Benefits of semaglutide have also been identified in people with a variety of other cardiometabolic and linked conditions, including metabolic liver disease 27 , diabetic kidney disease 28 , knee osteoarthritis 29 and peripheral artery disease 30 .”
Apperloo, E. M., Tuttle, K. R., Pavo, I., Haupt, A., Taylor, R., Wiese, R. J., Hemmingway, A., Cherney, D. Z. I., Sattar, N., & Heerspink, H. J. L. (2025) · Diabetes Care · doi:10.2337/dc24-1773 · Cited by 53
Self-citationOrandi, B. J., Chen, Y., Li, Y., Metoyer, G. T., Lentine, K. L., Weintraub, M. D., Bae, S., Ali, N. M., Lonze, B. E., Ren‐Fielding, C. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00371-1 · Cited by 62
Forny Germano, L., Koehler, J. A., Baggio, L. L., Cui, F., Wong, C. K., Rittig, N., Cao, X., Matthews, D., & Drucker, D. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102019 · Cited by 50
“Intriguingly, GLP-1RAs also reduce liver in fl ammation in people with metabolic liver disease [6] and reduce the rates of chronic kidney disease in people with T2D [7].”
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Awdishu, L., Maxson, R., Gratt, C., Rubenzik, T. T., & Battistella, M. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf044 · Cited by 71
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 146
Self-citationSilverii, G. A., Pala, L., Cresci, B., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16076 · Cited by 49
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
German, J., Cordioli, M., Tozzo, V., Urbut, S., Arumäe, K., Smit, R. A. J., Lee, J., Li, J. H., Janucik, A., Ding, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03645-3 · Cited by 65
“2 and Supplementary Tables 5 and 6).”
InfluentialGasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 59
“In the FLOW trial [13], which investigated the effect of once-weekly semaglutide in 3534 participants with T2DM and CKD, 15.5% received SGLT2is at baseline.”
InfluentialSelvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.023 · Cited by 49
Prevalence and Mortality of Cardiovascular-Kidney-Metabolic Syndrome in China
Zheng, C., Cai, A., Sun, M., Wang, X., Song, Q., Pei, X., Cao, X., Tian, Y., Lip, G. Y. H., Parati, G., et al. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.04.007 · Cited by 63
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 66
“Pooled analysis including these two studies in addition to SELECT and FLOW [31] reported that semaglu-tide reduced the risk of hospitalization or urgent visits due to heart failure by 41% (HR 0.59, 95% CI 0.41–0.82) in HFpEF patients compared with placebo [32].”
InfluentialSattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Fan, Y., Liu, Y., Shao, C., Jiang, C., Wu, L., Xiao, J., & Tang, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125486 · Cited by 62
“Additionally, some medications, such as somatostatin, lower the chance of clinical mortality from cardiovascular and renal reasons [127].”
Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease
Neuen, B. L., Yeung, E. K., Rangaswami, J., & Vaduganathan, M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae258 · Cited by 58
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
Lam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 59
“Supportive evidence shows that treatment with a GLP-1 receptor agonist (semaglutide 1 mg weekly) in people with type 2 diabetes and chronic kidney disease significantly reduced the risk of kidney disease progression, MACE, and cardiovascular or renal death by 24% compared to placebo [47].”
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.